American experts have assessed the resistance of the coronavirus to various types of vaccines. The factor of long-term stable action, regardless of virus mutations, has become one of the main factors in assessing the effectiveness of the drug. The results of the work were published in the scientific journal PLOS Biology.
Pennsylvania State University scientists David Kennedy and Andrew Reed have developed a three-step system for monitoring virus resistance to vaccines using standard test samples taken from subjects during vaccine clinical trials.
So, experts suggested analyzing blood samples for the number and type of antibodies and T cells. The more complex the immune response is given by the organism, the more stable immunity will be in the subject. In this case, the virus will have to mutate not once, but several times to infect the patient with the vaccine.
Secondly, scientists have proposed to examine nasal swabs for viral load and the likelihood of transmission. The absolute suppression of the virus will speak not only of the effectiveness of the injection, but also the prevention of transmission of the infection, and therefore the prevention of its mutation.
Third, experts advise using genetic data obtained from swabs to determine whether selection was based on a vaccine. Thus, significant genetic differences in virus samples from vaccinated and control individuals will indicate that selection has taken place, that is, partial resistance to the vaccine has appeared.
The Russian Center “Vector” previously identified more than 80 mutations of COVID-19, however, according to scientists, not all of them affect the effectiveness of the drug. The center stressed that the effectiveness of the Russian vaccine “EpiVacCorona” lies precisely in its resistance against mutations of the virus. This was achieved due to the fact that the drug was created on the basis of unchanging areas of COVID-19.